Research location
Krasnoyarsk
Russia
Advertisement
Research activity in Krasnoyarsk
RussiaCureCurrent currently publishes aggregate city-level research activity for this location: 157 trials and 176 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Krasnoyarsk
157 linked trials · page 1 of 4ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in RussiaNCT07399665 · 2025-12-25 · 1 site observation
RECRUITING
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in RussiaNCT06930859 · 2025-12-03 · 1 site observation
RECRUITING
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1NCT07292168 · 2025-12-02 · 1 site observation
RECRUITING
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDerationNCT07052578 · 2025-06-30 · 1 site observation
RECRUITING
Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry StudyNCT06521229 · 2024-06-27 · 1 site observation
RECRUITING
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)NCT06472310 · 2024-06-06 · 1 site observation
RECRUITING
The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.NCT03945968 · 2019-07-01 · 1 site observation
RECRUITING
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian FederationNCT07146113 · 2025-06-30 · 1 site observation
SUSPENDED
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With ExacerbationsNCT07597668 · 2025-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian FederationNCT06625333 · 2024-10-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast CancerNCT07386938 · 2024-08-09 · 1 site observation
ACTIVE_NOT_RECRUITING
PRospectIve ObseRvatIonal mulTicenter Study of Patients With Arterial hYpertension and CKD in the Population of RussiaNCT06372431 · 2024-04-27 · 1 site observation
COMPLETED
Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic AlterationsNCT06245837 · 2024-03-20 · 1 site observation
ACTIVE_NOT_RECRUITING
MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiANCT06422676 · 2023-12-29 · 1 site observation
COMPLETED
A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the RussiaNCT06148506 · 2023-12-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiANCT05939128 · 2023-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in RussiaNCT05905939 · 2023-05-31 · 1 site observation
COMPLETED
HER2-low Unresectable and/or Metastatic Breast Cancer in RussiaNCT05913440 · 2023-05-30 · 1 site observation
COMPLETED
Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus PatientsNCT07070752 · 2023-04-14 · 1 site observation
COMPLETED
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in RussiaNCT05887011 · 2023-03-31 · 1 site observation
ACTIVE_NOT_RECRUITING
A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in RussiaNCT05456867 · 2022-05-31 · 1 site observation
ACTIVE_NOT_RECRUITING
An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCADNCT06987851 · 2022-03-22 · 1 site observation
COMPLETED
Exacerbations and Their Outcomes International (EXACOS International)NCT04928417 · 2021-11-26 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05134441 · 2021-11-18 · 1 site observation
ACTIVE_NOT_RECRUITING
A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in RussiaNCT04943497 · 2021-07-27 · 1 site observation
COMPLETED
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)NCT04777396 · 2021-05-18 · 1 site observation
COMPLETED
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)NCT04777409 · 2021-05-18 · 1 site observation
COMPLETED
Heart Failure Patients RegistryNCT04709263 · 2020-12-21 · 1 site observation
COMPLETED
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerNCT04351555 · 2020-12-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsNCT04538664 · 2020-10-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT04487080 · 2020-09-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)NCT04411641 · 2020-09-24 · 1 site observation
COMPLETED
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)NCT04458051 · 2020-08-13 · 1 site observation
COMPLETED
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)NCT04477707 · 2020-07-23 · 1 site observation
COMPLETED
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)NCT04385368 · 2020-07-17 · 1 site observation
COMPLETED
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)NCT04338061 · 2020-07-02 · 1 site observation
TERMINATED
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)NCT04410978 · 2020-06-30 · 1 site observation
COMPLETED
Study of Evobrutinib in Participants With RMS (evolutionRMS 1)NCT04338022 · 2020-06-12 · 1 site observation
TERMINATED
Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)NCT04333147 · 2020-05-12 · 1 site observation
TERMINATED
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in RussiaNCT04315688 · 2020-03-30 · 2 site observations
COMPLETED
Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus PatientsNCT04226105 · 2020-01-20 · 1 site observation
UNKNOWN
An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisNCT04130997 · 2019-11-18 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian FederationNCT04138199 · 2019-11-01 · 1 site observation
TERMINATED
House Dust Mite Allergy Trial In ChildrenNCT04145219 · 2019-10-12 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor FluctuationsNCT04006210 · 2019-09-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)NCT03940703 · 2019-09-19 · 1 site observation
COMPLETED
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureNCT04095793 · 2019-09-19 · 2 site observations
TERMINATED
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03NCT04109391 · 2019-08-20 · 1 site observation
COMPLETED
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate CancerNCT04028388 · 2019-07-17 · 1 site observation
COMPLETED
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)NCT03970837 · 2019-06-05 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.